Yayın:
Methotrexate intoxication: Beyond the adverse events

dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.buuauthorCoşkun, Belkıs Nihan
dc.contributor.buuauthorYağız, Burcu
dc.contributor.buuauthorTufan, Ayşe Nur
dc.contributor.buuauthorErmurat, Selime
dc.contributor.buuauthorPehlivan, Yavuz
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentRomatoloji Ana Bilim Dalı
dc.contributor.orcid0000-0003-0298-4157
dc.contributor.researcheridAAG-7155-2021
dc.contributor.researcheridABE-4424-2022
dc.contributor.researcheridAAG-8227-2021
dc.contributor.scopusid6506739457
dc.contributor.scopusid55646165400
dc.contributor.scopusid57203458191
dc.contributor.scopusid56076552900
dc.contributor.scopusid55371331300
dc.contributor.scopusid13205593600
dc.date.accessioned2023-10-31T12:17:49Z
dc.date.available2023-10-31T12:17:49Z
dc.date.issued2018-08
dc.description.abstractAim: Methotrexate (MTX) is the first-line disease-modifying antirheumatic drug in rheumatoid arthritis (RA). However, this anchor may cause some side effects that may range from nausea to mortality. The clinical features of MTX toxicity are under-researched. In this study, we aimed to find out the potential predisposing factors and outcomes of the MTX toxicity (n = 31). Methods: The data were collected from 31 patients whose ages ranged from 25 to 81 years, who were suffering from immune-mediated inflammatory diseases and major MTX-related toxicity. Results: Out of 31 patients, six (19.4%) used MTX every day, and 13 (41.9%) patients had renal insufficiency who were admitted to the hospital because of mucositis (90.3%) and fever (71%). While using MTX, 27 patients (87.1%) were discharged after the treatment and four patients (12.9%) died. Conclusions: Although MTX has high efficacy for the toxicity ratio, wrong use and dosage of MTX may be harmful to patients. Thus, patients should be informed about the proper use of MTX.
dc.identifier.citationDalkılıç, E. vd. (2018). ''Methotrexate intoxication: Beyond the adverse events''. International Journal of Rheumatic Diseases, 21(8), 1557-1562.
dc.identifier.doi10.1111/1756-185X.13339
dc.identifier.endpage1562
dc.identifier.issn1756-1841
dc.identifier.issn1756-185X
dc.identifier.issue8
dc.identifier.pubmed30146743
dc.identifier.scopus2-s2.0-85052205923
dc.identifier.startpage1557
dc.identifier.urihttps://doi.org/10.1111/1756-185X.13339
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/1756-185X.13339
dc.identifier.urihttp://hdl.handle.net/11452/34699
dc.identifier.volume21
dc.identifier.wos000442740000011
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWiley
dc.relation.journalInternational Journal of Rheumatic Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRheumatology
dc.subjectMethotrexate
dc.subjectMethotrexate toxicity
dc.subjectRenal insufficiency
dc.subjectLow-dose methotrexate
dc.subjectRheumatoid-arthritis
dc.subjectAcid supplementation
dc.subjectInduced pancytopenia
dc.subjectFolinic acid
dc.subjectToxicity
dc.subjectTherapy
dc.subject.emtreeAcemetacin
dc.subject.emtreeAcetylsalicylic acid
dc.subject.emtreeAntibiotic agent
dc.subject.emtreeDiclofenac
dc.subject.emtreeFilgrastim
dc.subject.emtreeFolinate calcium
dc.subject.emtreeIbuprofen
dc.subject.emtreeIndometacin
dc.subject.emtreeMethotrexate
dc.subject.emtreeNonsteroid antiinflammatory agent
dc.subject.emtreeOmeprazole
dc.subject.emtreeRamipril
dc.subject.emtreeAntirheumatic agent
dc.subject.emtreeMethotrexate
dc.subject.emtreeAdult
dc.subject.emtreeAged
dc.subject.emtreeArticle
dc.subject.emtreeClinical article
dc.subject.emtreeCoughing
dc.subject.emtreeDeath
dc.subject.emtreeDisease predisposition
dc.subject.emtreeDose calculation
dc.subject.emtreeDrug efficacy
dc.subject.emtreeDrug information
dc.subject.emtreeDrug intoxication
dc.subject.emtreeDrug megadose
dc.subject.emtreeDrug misuse
dc.subject.emtreeDrug potentiation
dc.subject.emtreeFemale
dc.subject.emtreeFever
dc.subject.emtreeHeadache
dc.subject.emtreeHospital admission
dc.subject.emtreeHospital discharge
dc.subject.emtreeHuman
dc.subject.emtreeInfection
dc.subject.emtreeInflammatory disease
dc.subject.emtreeKidney failure
dc.subject.emtreeLongitudinal study
dc.subject.emtreeMale
dc.subject.emtreeMiddle aged
dc.subject.emtreeMucosa inflammation
dc.subject.emtreeMycosis fungoides
dc.subject.emtreeNausea
dc.subject.emtreeOpen study
dc.subject.emtreeOutcome assessment
dc.subject.emtreePatient risk
dc.subject.emtreePneumonia
dc.subject.emtreePriority journal
dc.subject.emtreePsoriatic arthritis
dc.subject.emtreePurpura
dc.subject.emtreeRetrospective study
dc.subject.emtreeRheumatoid arthritis
dc.subject.emtreeSjoegren syndrome
dc.subject.emtreeSystemic sclerosis
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeVery elderly
dc.subject.emtreeChemically induced
dc.subject.emtreeCommunicable disease
dc.subject.emtreeDose response
dc.subject.emtreeDrug interaction
dc.subject.emtreeFever
dc.subject.emtreeKidney failure
dc.subject.emtreeMedication error
dc.subject.emtreeMortality
dc.subject.emtreeMucosa inflammation
dc.subject.emtreeRisk assessment
dc.subject.emtreeRisk factor
dc.subject.emtreeThrombocytopenic purpura
dc.subject.emtreeTurkey (bird)
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntirheumatic agents
dc.subject.meshArthritis, rheumatoid
dc.subject.meshCommunicable diseases
dc.subject.meshDose-response relationship, drug
dc.subject.meshDrug interactions
dc.subject.meshFemale
dc.subject.meshFever
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMedication errors
dc.subject.meshMethotrexate
dc.subject.meshMiddle aged
dc.subject.meshMucositis
dc.subject.meshPurpura, thrombocytopenic
dc.subject.meshRenal insufficiency
dc.subject.meshRetrospective studies
dc.subject.meshRisk assessment
dc.subject.meshRisk factors
dc.subject.meshTurkey
dc.subject.scopusMethotrexate; Rheumatoid Arthritis; Pustulosis Palmoplantaris
dc.subject.wosRheumatology
dc.titleMethotrexate intoxication: Beyond the adverse events
dc.typeArticle
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Romatoloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama